Nuclear Medicine and Biology
Volume 34, Issue 5 , Pages 503-510 , July 2007

Chemical design of a radiolabeled gelatinase inhibitor peptide for the imaging of gelatinase activity in tumors

  • Hirofumi Hanaoka

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Kyoto 606-8501, Japan
    • Graduate School of Medicine, Gunma University, Maebashi 371-8511, Japan
    • ,
  • Takahiro Mukai

      Affiliations

    • Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
    • Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan
    • ,
  • Sayo Habashita

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Kyoto 606-8501, Japan
    • ,
  • Daigo Asano

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Kyoto 606-8501, Japan
    • ,
  • Kazuma Ogawa

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Kyoto 606-8501, Japan
    • ,
  • Yoshihiro Kuroda

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Kyoto 606-8501, Japan
    • ,
  • Hiromichi Akizawa

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan
    • ,
  • Yasuhiko Iida

      Affiliations

    • Graduate School of Medicine, Gunma University, Maebashi 371-8511, Japan
    • ,
  • Keigo Endo

      Affiliations

    • Graduate School of Medicine, Gunma University, Maebashi 371-8511, Japan
    • ,
  • Tsuneo Saga

      Affiliations

    • Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
    • ,
  • Hideo Saji

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Kyoto 606-8501, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 75 753 4556; fax: +81 75 753 4568.

Received 27 March 2007 ,Accepted 4 April 2007.

References 

  1. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274:21491–21494
  2. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463–516
  3. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999;43:S42–S51
  4. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135–1149
  5. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 2001;7:14–23
  6. Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Östör AG, et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer. 2002;94:1466–1475
  7. Hrabec E, Strek M, Nowak D, Greger J, Suwalski M, Hrabec Z. Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis. J Cancer Res Clin Oncol. 2002;128:197–204
  8. Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer. 2002;86:1876–1883
  9. Edwards JG, McLaren J, Jones JL, Waller DA, O'Byrne KJ. Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer. 2003;88:1553–1559
  10. Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev. 1999;99:2735–2776
  11. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93:178–193
  12. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002;295:2387–2392
  13. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkilä P, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 1999;17:768–774
  14. Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev. 2004;24:357–397
  15. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooij PPM, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–731
  16. van Hagen PM, Breeman WAP, Bernard HF, Schaar M, Mooij CM, Srinivasan A, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer. 2000;90:186–198
  17. Akizawa H, Arano Y, Mifune M, Iwado A, Saito Y, Mukai T, et al. Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides. Nucl Med Biol. 2001;28:761–768
  18. Akizawa H, Takimoto H, Saito M, Iwado A, Mifune M, Saito Y, et al. Effect of carboxylation of N-terminal phenylalanine of 111In-DTPA (diethylenetriaminepentaacetic acid)-octreotide on accumulation of radioactivity in kidney. Biol Pharm Bull. 2004;27:271–272
  19. Arano Y, Uezono T, Akizawa H, Ono M, Wakisaka K, Nakayama M, et al. Reassessment of diethylenetriaminepentaacetic acid (DTPA) as a chelating agent for indium-111 labeling of polypeptides using a newly synthesized monoreactive DTPA derivative. J Med Chem. 1996;39:3451–3460
  20. Arano Y, Wakisaka K, Ohmomo Y, Uezono T, Mukai T, Motonari H, et al. Maleimidoethyl 3-(tri-n-butylstannyl)hippurate: a useful radioiodination reagent for protein radiopharmaceuticals to enhance target selective radioactivity localization. J Med Chem. 1994;37:2609–2618
  21. Arano Y, Akizawa H, Uezono T, Akaji K, Ono M, Funakoshi S, et al. Conventional and high-yield synthesis of DTPA-conjugated peptides: application of a monoreactive DTPA to DTPA-d-Phe1-octreotide synthesis. Bioconjug Chem. 1997;8:442–446
  22. Albert R, Miller K, Chong R, Hirth W, Vanderheyden J-L, Deutsch K, et al. Characterization of the two diastereomers of octreoscan-111, an In-111 labeled peptide for use in cancer imaging. J Nucl Med. 1992;33:900;[abstract]
  23. Akizawa H, Arano Y, Mifune M, Iwado A, Saito Y, Uehara T, et al. Significance of 111In-DTPA chelate in renal radioactivity levels of 111In-DTPA-conjugated peptides. Nucl Med Biol. 2001;28:459–468
  24. Schultz RM, Silberman S, Persky B, Bajkowski AS, Carmichael DF. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res. 1988;48:5539–5545
  25. Alvarez OA, Carmichael DF, DeClerck YA. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst. 1990;82:589–595
  26. Giersing BK, Rae MT, CarballidoBrea M, Williamson RA, Blower PJ. Synthesis and characterization of 111In-DTPA-N-TIMP-2: a radiopharmaceutical for imaging matrix metalloproteinase expression. Bioconjug Chem. 2001;12:964–971
  27. Kulasegaram R, Giersing B, Page CJ, Blower PJ, Williamson RA, Peters BS, et al. In vivo evaluation of 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection. Eur J Nucl Med. 2001;28:756–761
  28. Furumoto S, Iwata R, Ido T. Design and synthesis of fluorine-18 labeled matrix metalloproteinase inhibitor for cancer imaging. J Labelled Compd Radiopharm. 2002;45:975–986
  29. Zheng Q-H, Fei X, Liu X, Wang J-Q, Sun HB, Mock BH, et al. Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol. 2002;29:761–770
  30. Furumoto S, Takashima K, Kubota K, Ido T, Iwata R, Fukuda H. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol. 2003;30:119–125
  31. Zheng Q-H, Fei X, DeGrado TR, Wang J-Q, Stone KL, Martinez TD, et al. Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [11C]methyl ester. Nucl Med Biol. 2003;30:753–760
  32. Kuhnast B, Bodenstein C, Wester HJ, Weber W. Carbon-11 labelling of an N-sulfonylamino acid derivative: a potential tracer for MMP-2 and MMP-9 imaging. J Labelled Compd Radiopharm. 2003;46:539–553
  33. Zheng Q-H, Fei X, Liu X, Wang J-Q, Stone KL, Martinez TD, et al. Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2- (4′-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4′-[11C]methoxyphenyl)sulfonyl]benzylamino]-3-methylbutanamide. Nucl Med Biol. 2004;31:77–85
  34. Li WP, Anderson CJ. Imaging matrix metalloproteinase expression in tumors. Q J Nucl Med. 2003;47:201–208
  35. Kuhnast B, Bodenstein C, Haubner R, Wester HJ, Senekowitsch-Schmidtke R, Schwaiger M, et al. Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. Nucl Med Biol. 2004;31:337–344
  36. Van H, Wart E, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A. 1990;87:5578–5582
  37. Morgunova E, Tuuttila A, Bergmann U, Isupov M, Lindqvist Y, Schneider G, et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science. 1999;284:1667–1670

PII: S0969-8051(07)00097-2

doi: 10.1016/j.nucmedbio.2007.04.002

Nuclear Medicine and Biology
Volume 34, Issue 5 , Pages 503-510 , July 2007

Article Tools

* Image Usage & Resolution